Search results
Results from the WOW.Com Content Network
Mads Krogsgaard Thomsen worked as a pharmacologist at Leo Pharmaceutical Products from 1989 to 1991 and was thereafter employed by Novo Nordisk in as head of Growth Hormone Research. He became senior vice president for diabetes R&D in 1994 and was appointed senior vice president of Health Care Discovery in 1995.
The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt, denoted by the hieroglyph 𓃒. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). [8]
In 1991, Jørgensen joined Novo Nordisk as an economist in Health Care, Economy & Planning. He was appointed as vice-president for IT and Corporate Development in 2004. In January 2013, he was appointed as executive vice president and chief information officer. In November 2014 oversaw Corporate People & Organization and Business Assurance. [4]
Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity care.. The company develops a long line of blockbuster glucagon-like ...
The company, the investment arm of the Novo Nordisk Foundation, has 77% of voting shares in Novo Nordisk that makes the blockbuster obesity drug Wegovy and diabetes treatment Ozempic. Novo ...
The committee found earlier this year that Novo Nordisk charges Americans with diabetes $969 a month for Ozempic, while in Canada it costs $155 a month and in Germany, $59. For Wegovy, the ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Novo Nordisk said Friday it settled two lawsuits against two businesses claiming to offer compounded versions of its blockbuster drugs Ozempic and Wegovy.. The drugmaker has filed a total of 12 ...